DelveInsight’s Uterine Fibroids Market Report covers historical and forecasted epidemiology, as well as Uterine Fibroids market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan).
Some of the Key Highlights from Uterine Fibroids Market Report
According to Yu et al., 2018 report, “A US population-based study of uterine fibroid diagnosis incidence, patterns, and prevalence: 2005 through 2014,” Uterine Fibroids is a common health issue, with a prevalence rate of nearly 10%. Symptomatic Uterine Fibroids can affect up to 25% of all women and up to 30%–40% of women in their premenopausal years. The proportion of women with fibroids was highest (15.9%) in the age group 50–54 years, with prevalence marginally lower (13.4%) in the age groups on either side.
According to the study conducted by Giuliani et al. (2020) titled “Epidemiology and management of uterine fibroids”, annual direct and indirect costs of Uterine Fibroids are projected to be as high as USD 4.4 billion in the United States, with gross annual costs of USD 348 million in Germany, USD 120 million in France, and USD 86 million in the United Kingdom.
Yselty (ObsEva), and Orgovyx (Myovant Sciences) are some of the emerging therapies among others in the Uterine Fibroids market.
Key pharmaceutical companies actively working in the Uterine Fibroids market include ObsEva, Myovant Sciences, among others.
Learn more by requesting sample @ Uterine Fibroids Market Insights
The Uterine Fibroids market report offers analysis segmented into 7MM including new therapeutic practises, emerging drugs, individual therapy market shares, and existing and forecasted Uterine Fibroids market sizes from 2018 to 2030. The report also examines current Uterine Fibroids management practice/algorithm in order to curate the best of the opportunities and assess the market’s underlying potential.
Uterine Fibroids: Disease Overview
Uterine Fibroids (Uterine leiomyomata) are non-cancerous growths of the uterus that most often affect women during their reproductive years. A woman may have a single fibroid or a large number of them, causing extreme abdominal pain and heavy periods. In certain cases, they produce no symptoms at all. Fibroids are common in women during their reproductive years.
Uterine Fibroids Epidemiology Segmentation
Uterine Fibroids Prevalent Population
Uterine Fibroids Age-Specific Prevalent Population
Uterine Fibroids Diagnosed and Treatable Cases
Uterine Fibroids Treatment Landscape
Uterine fibroids can be treated in a variety of ways, from none at all to surgery. Treatment is normally not needed unless fibroids are causing excessive bleeding, discomfort, or bladder problems.
Current treatment options for Uterine Fibroids are:
Simple Pain Relief Medications (paracetamol, non-steroidal anti-inflammatory drugs (NSAIDS), codeine, and others)
Birth control (oral contraceptive pills, contraception, injections, IUDs )
GnRH Receptor Agonists (Elagolix, Lupron Depot, Oriahnn, Zoladex, Trelstar, and others)
Testosterone Derivatives (Danocrine and gestrinone)
Aromatase inhibitors (Femara and Arimidex)
Surgery (Laparoscopy, Laparotomy, Myomectomy, and Hysterectomy)
Uterine Fibroids Market
In the seven Major Markets, the total market size of Uterine Fibroids would include the market size of both possible upcoming treatments or therapies like Yselty (ObsEva), Orgovyx (Myovant Sciences), and existing treatment regimens.
For more information visit Uterine Fibroids Market Trends and Treatment Landscape
Uterine Fibroids Pipeline Therapies and Key Companies
Orgovyx: Myovant Sciences
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)
Study Period: 2018-30
Uterine Fibroids Key Companies: ObsEva,Myovant Sciences, among others.
Uterine Fibroids Key Pipeline Therapies: Yselty (ObsEva), Orgovyx (Myovant Sciences), and others.
Uterine Fibroids Market Segmentation: By Geography, By Uterine Fibroids therapies
Analysis: Comparative and conjoint analysis of Uterine Fibroids emerging therapies
Tools Used: SWOT Analysis
Table of Contents
Uterine Fibroids: Market Overview at a Glance
Disease Background and Overview: Uterine Fibroids
Uterine Fibroids Epidemiology and Patient Population (7MM)
Uterine Fibroids : Country-Wise Epidemiology
Uterine Fibroids Treatments and Medical Practices
Uterine Fibroids Current Treatment
Uterine Fibroids Emerging Therapies
Uterine Fibroids : Market Size
7MM: Country-Wise Market Analysis
United States Market Size
EU5 Market Size
Japan Market Size
Uterine Fibroids Market Drivers
Uterine Fibroids Market Barriers
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Uterine Sarcoma Market
Get comprehensive historical and forecast analysis of Uterine Sarcoma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Pfizer Inc., Intas Pharmaceuticals Ltd., FMC Corporation, Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., General Electric Company, Koninklijke Philips N.V., Siemens Healthcare Private Limited, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States